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Organotin compounds such as triphenyltin (TPT) and tributyltin (TBT) act as endocrine disruptors
through the peroxisome proliferator–activated receptor c (PPARc) signaling pathway. We recently found
that TPT is a particularly strong agonist of PPARc. To elucidate the mechanism underlying
organotin-dependent PPARc activation, we here analyzed the interactions of PPARc ligand-binding
domain (LBD) with TPT and TBT by using X-ray crystallography and mass spectroscopy in conjunction
with cell-based activity assays. Crystal structures of PPARc-LBD/TBT and PPARc-LBD/TPT complexes
were determined at 1.95 Å and 1.89 Å, respectively. Specific binding of organotins is achieved through
non-covalent ionic interactions between the sulfur atom of Cys285 and the tin atom. Comparisons of the
determined structures suggest that the strong activity of TPT arises through interactions with helix 12 of
LBD primarily via p-p interactions. Our findings elucidate the structural basis of PPARc activation by TPT.
T
he peroxisome proliferator-activated receptors (PPARs), subtypes of which have been identified as a, c, and
d, belong to the nuclear receptor superfamily and act as transcription factors to control the expression of
target genes. PPARs form heterodimers with retinoid X receptor (RXR) and bind to specific regions on
various genes1. It has been well established that PPARc regulates the expression of the genes responsible for
adipocyte differentiation. Furthermore, PPARc has been found in trophoblasts, where it serves as an essential
regulator of placental differentiation and has other endocrine functions, including the production of human
chorionic gonadotropin (hCG) and in steroidogenesis2–4.
Organotin compounds have been widely used as antifouling biocides for ships, agricultural fungicides, and so
on5,6. However, their widespread use has deleteriously affected marine ecosystems. At very low concentrations,
organotin compounds such as triphenyltin (TPT) and tributyltin (TBT) induce ‘‘imposex’’, which is the mascu-
linization of female gastropod mollusks7. Hence these tin compounds came to be known as endocrine-disrupting
chemicals. In mammals, organotins also have various undesirable effects on immune mechanisms and metabolic
activity5,8. We previously investigated the effects of organotins on PPARc and showed that: (1) TPT and TBT at
nanomolar concentrations enhance hCG production in human choriocarcinoma cells and stimulate adipocyte
differentiation; (2) the endocrine disruptive action of organotins is mediated through the PPARc-dependent
pathway; (3) TPT has considerably stronger agonistic activity toward PPARc than does TBT; and (4) tri-alkyl
and aromatic tin compounds have stronger agonist activities than do tetra-, di- and monosubstituted
compounds9–14.
Recently, a crystal structural analysis of the RXRa/TBT complex was performed that provided insights into
how TBT activates the RXRa-PPARc signaling pathway15; transactivation by organotins was attributed to RXRa,
not to PPARc, because of the weak agonistic activity of TBT toward PPARc. In addition, the study15 reported that
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(Cys432) located in helix 11 (H11) of RXRa. Stabilization of this
secondary structural element is believed to be essential to modulate
transcriptional activity. Due to the absence of a cysteine residue at the
corresponding position in PPARc, the authors of the study15 con-
cluded that the binding of organotin compounds to PPARc alone
does not allow efficient transactivation. Therefore, our finding that
TPT acts as a powerful PPARc agonist9 suggests the need to clarify
the structural basis for PPARc transactivation by tin compounds in
order to better understand the mechanism of RXR-PPARc signaling
via these compounds.
Since the first structural determination of the PPARc ligand-bind-
ing domain (LBD) was reported by using X-ray crystallography16,
multiple structures in both the apo and liganded forms have been
determined. From these studies, activation mechanisms induced by
various well-known PPARc agonists, including thiazolidinediones
(TZD) such as rosiglitazone, have been discovered. The binding of
the agonist to the ligand-binding pocket of LBD causes its helix 12
(H12) to form an active conformation that promotes the recruitment
of a transcriptional coactivator. However, the mechanism of trans-
activation by tin compounds with various substituted organic
groups, which are distinct from well-known PPARc agonists with
respect to their structural and chemical features (see Supplementary
Fig. S1 online), is still poorly understood and cannot be inferred
based on previously known structures. Therefore, to elucidate the
mechanism, here we determined the three-dimensional structures of
PPARc-LBD in complexes with TPT and TBT, respectively, and
characterized these complexes by using mass spectrometry (MS)
and biological activity assays.
Results
Structural determination of the PPARc complexes. Crystals of
PPARc-LBD in complex with TPT and TBT, respectively, were
obtained by co-crystallization. They belong to the same space
group P21 with similar cell dimensions. The structures determined
at 1.95 Å (PPARc-LBD/TBT) and 1.89 Å (PPARc-LBD/TPT)
resolutions (Table 1) were revealed to have the typical nuclear
receptor fold that comprises an a-helical sandwich fold (12 helices)
with a four-stranded b-sheet. In an asymmetric unit, two PPARc-
LBD molecules were found. These structural data have been
deposited in the Protein Data Bank database under the accession
numbers 3WJ4 and 3WJ5. Both crystals contained two LBDs
(chain A and B) in the asymmetric unit, where each LBD was
bound to one ligand. The structure of chain A assumed an ‘‘active’’
conformation that was found in the PPARc-LBD/agonist/co-
activator peptide complex (PDB No. 2PRG)16, where helix 12
(H12) of LBD exists in a position suitable to interact with the
agonist and to form the binding site of the co-activator. By
contrast, in the other molecule (chain B), H12 was displaced from
the ligand-binding pocket, preventing the co-activator from binding
to the LBD, possibly due to extensive interactions with symmetry-
related neighboring molecules in the crystal (see Supplementary Fig.
S2 online). Because PPARc transactivation is induced by the ‘‘active’’
conformation of H12, we hereafter focused on the structure of chain
A (Figure 1).
The exact positions of the ligands were determined by using an
anomalous difference map derived from the tin anomalous signals
(Figure 2). Although the structural analyses showed ligands with
Table 1 | Data collection and structural refinement statistics
PPARc-LBD/TBT PPARc-LBD/TPT
Data Collection
Beamline Photon factory BL-6A Photon factory BL-17A
Wavelength (Å) 1.0000 0.9800
Space group P21 P21
Cell dimensions
a, b, c (Å) 56.34, 88.29, 57.51 56.52, 88.49, 57.94
a, b, c (u) 90.00, 90.68, 90.00 90.00, 91.01, 90.00
Resolution range (Å) 50.00-1.95 (1.98-1.95) 50.00-1.89 (1.92-1.89)
Rmergeb 0.066 (0.352) 0.064 (0.372)
,I/sI. 43.25 (7.2) 44.12 (6.3)
Completeness (%) 100 (100) 99.8 (99.5)
Redundancy 7.6 (7.5) 7.6 (7.3)
Refinement
Resolution (Å) 36.438-1.95 (2.00–1.95) 36.515-1.89 (1.94–1.89)
No. reflections 38942 43047
Rwork (%) 0.194 (0.218) 0.203 (0.233)
Rfree (%) 0.241 (0.270) 0.247 (0.247)





Overall (Å2) 25.4 24.0
Protein (Å2) 25.0 23.7
Ligand (Å2) 33.2 48.2
Water (Å2) 26.2 26.2
R.M.S. deviations
Bond length (Å) 0.017 0.017
Bond angles (u) 1.627 1.516
Ramachandran plot statistics
Most favored (%) 98.62 98.81
Additional allowed (%) 1.38 0.99
Disallowed (%) 0.00 0.20
aValues in parentheses are for the highest resolution shell.
bRmerge 5
P | Ih 2 ,Ih. | /PIh, where ,Ih. is the average intensity of reflection h and symmetry-related reflections.
www.nature.com/scientificreports
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relatively low electron densities (Figure 2) and large B factors
(Table 1), clear anomalous signals corresponding to tin atoms were
found in close proximity to the sulfur atom of Cys285, which exists in
the central region of the ligand-binding pocket. This finding suggests
that specific interactions occur between the tin and sulfur atoms. In
the TBT complex, only one anomalous peak was identified at the side
of the b-strand (B3), at a distance of 2.54 Å from the sulfur atom of
Cys285. In contrast, the TPT complex had a major (16s) and a minor
(5s) anomalous peak around Cys285, which were associated with
two alternative binding sites for TPT. Refinements provided the
model with the occupancy of TPT molecule at the major site is
80%. Intriguingly, despite the structural similarities of the ligands,
the major TPT complex was close to H12, which was on the opposite
side of Cys285 from the position of TBT. The distance between the
tin atom and the sulfur atom of Cys285 was 2.74 Å (Figure 2). For
both complexes, the Sn-S lengths were longer than the sum of the
covalent radii (2.42 Å) and equal to, or slightly longer than, the sum
of the ionic radii (2.54 Å) of tin and sulfur, suggesting that the Sn-S
bond is non-covalent and ionic rather than covalent, as previously
observed in the crystal structure of the RXRa/TBT complex.
The PPARc ligand-binding pocket is surrounded by secondary
elements, B3, H3, H5, H7, H11, and H12. Cys285 in H3 serves an
anchor for the tin atom to interact with the residues lining the pocket,
which are predominantly hydrophobic in character, by using the
alkylic or aromatic moieties of the organotins. Both ligands share
common interacting residues, namely Ile281 (H3), Phe282 (H3),
Ile326 (H5), Tyr327 (H5), Phe360 (H7), Phe363 (H7), Met364
(H7), and His449 (H11). Besides these residues, TPT also interacts
with Gln286 (H3), Ser289 (H3), Leu330 (H5), Lys367 (H7), Leu453
(H11), Leu469 (H12), and Tyr473 (H12). In contrast, TBT interacts
with Val339 (B3) and Ile341 (B3) (Figure 3).
Activity of tin compounds as PPARc agonists. To evaluate the
functional potency of tin compounds as PPARc agonists, we
performed reporter assays using the PPARc-specific GAL4-luc
system, where wild-type PPARc-LBD is fused to the GAL4 DNA-
binding domain and a luciferase reporter gene is under the control of
GAL4 binding elements (Figure 4). TPT (100 nM) enhanced the
transactivation function of PPARc by 11-fold, and this level of
activation was comparable to that of rosiglitazone, a representative
full agonist for PPARc. However, although lower concentrations of
TPT and TBT provided similar responses to that of rosiglitazone,
100 nM TBT showed only half the level of activation achieved with
rosiglitazone and TPT. These results indicate that, despite similar
structural and chemical features, TPT and TBT differ in their PPARc
transactivation and/or binding.
To verify the involvement of the p-p interaction in the full-agon-
istic activity of TPT, we substituted Phe363 of PPARc with alanine
Figure 3 | Interactions of PPARc-LBD with TBT (A) or TPT (B). Ligands
are shown as cyan and yellow sticks. Ligand-interacting residues, which are
close (within 4.2 Å) to the ligands, are also shown. Common interacting
residues for both ligands are shown as gray sticks. Interacting residues for
TBT or TPT only are show in green or pink, respectively.
Figure 1 | Structures of the PPARc-LBD complex with TBT (A) and TPT
(B).
Figure 2 | The organotins ((A): TBT, (B): TPT) and Cys285 in the ligand-
binding pocket of PPARc. Anomalous difference electron density maps
contoured at 3.5s (red) indicate the position of the tin atom and omit
2FO–FC electron density maps contoured at 0.5s (cyan) indicate the
geometry of the aliphatic or aromatic chain. Distances between the tin and
sulfur atoms are indicated. In panel (B), the major and minor
conformations of TPT are shown in yellow and gray, respectively.
www.nature.com/scientificreports
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and carried out the cell-based assay. In the case of TPT, the tran-
scriptional activity of the mutant was about three-fold lower than
that of wild-type, whereas no significant difference in activity was
observed for TBT upon the introduction of the mutation (Figure 4).
Characterization of organotin binding to PPARc Cys285. The
PPARc mutant with its Cys285 replaced to alanine was not
activated by TBT and TPT (Figure 4). Thus, as was previously
shown for RXR15, the specific interaction between the cysteine
residue and the tin atom is essential for the activation of PPARc by
organotins. However, our structural data suggested that the Sn-S
bonds in PPARc complexes are ionic in nature, in contrast to the
covalent bond reported for the RXRa-LBD/TBT complex15. To
clarify whether complex formation of PPARc-LBD with tin
compounds is mediated through covalent or non-covalent
bonding, we performed MS analysis under non-denaturing
conditions for PPARc-LBD complexes with TPT or TBT
(Figure 5). The results indicated that the complexes of PPARc with
these organotins formed in 151 molar ratios (Figure 5C and 5E). No
free PPARc-LBD was detected in these spectra and even under highly
stringent ionization conditions of up to 190 V of sample cone voltage
(Vc), the complex peaks were not disrupted, indicating that the
complexes for both cases were highly stable.
On the other hand, the addition of aliquots of formic acid to the
mixtures, which should induce PPARc-LBD unfolding, resulted in
different MS patterns (Figure 5A, B, and D). The newly emerged ion
series under the partially (Figure 5B) or fully (Figure 5A and 5D)
PPARc-LBD unfolded conditions yielded the molecular mass of free
PPARc-LBD (31,370.6 Da), indicating the dissociation of TPT or
TBT from PPARc-LBD upon the acid-induced unfolding of
PPARc-LBD in the mixture. Furthermore, the addition of a sufficient
amount of formic acid to the mixture of PPARc-LBD and TPT led to
the complete disappearance of the peaks for the PPARc-LBD/TPT
complex, whereas, in addition to the peaks of unfolded PPARc-LBD,
the peak of dissociated TPT was consistently observed as a singly
charged species with a molecular mass of 350.1 Da (see
Supplementary Fig. S3 online). In the previous study15, they pro-
posed that TBT is connected to RXRa through a ‘‘covalent bond’’
involving the sulfur atom of RXRa Cys432 based on the crystal
structure and on MS results that showed no disruption of the
RXRa-LBD/TBT complex even when highly stringent parameters
(Vc: 190 V) were applied. Similar to their results, in our current
study, the PPARc-LBD/TPT and PPARc-LBD/TBT complexes were
retained even under highly stringent conditions (Vc: 190 V).
However, our current structural study clearly showed the absence
of a covalent bond in the PPARc-LBD/TPT and PPARc-LBD/TBT
complexes. Given that little or no dissociation of protein metal com-
plexes in the gas phase has been observed in the mass spectra of metal
complexes17,18 and that hydrogen bonding and electrostatic interac-
tions are maintained to a greater extent than are hydrophobic (van
der Waals) interactions19, the retention of the non-covalent interac-
tions of nuclear receptors/organotin complexes under non-denatur-
ing MS conditions with highly stringent parameters is not
unexpected. We also performed MS analysis under fully denaturing
conditions in which a covalently-bound 15-deoxy-D12,14-pros-
taglandin J2 (15d-PGJ2)20 did not dissociate from PPARc-LBD while
a non-covalent ligand, rosiglitazone, did. The results demonstrated
that the complexes of PPARc with organotins dissociates in the
denaturing conditions (see Supplementary Fig. S4 online).
Therefore, we re-investigated the binding mode of the RXRa-
LBD/TBT interaction by performing an MS analysis of the RXRa-
LBD/TBT mixture. Consistent with the previous report15, peaks of
RXRa-LBD/TBT complex with similar charge states could be
observed without disruption of the complex formation. However,
the bound TBT was dissociated with ease when RXRa was partially
or completely unfolded by the addition of acetonitrile or formic acid
to the solution (see Supplementary Fig. S5 online). These results
indicate that TBT is bound to RXRa via a non-covalent interaction.
Taken together, we conclude that TPT and TBT bind to PPARc
principally via a non-covalent, ionic bond between the tin atom and
Cys285 that requires the correct folding of PPARc-LBD, which pro-
vides appropriate electrostatic and van der Waals interactions.
Figure 4 | Cell-based transcriptional activation assay of rosiglitazone, TPT, and TBT on wild-type, C285A, and F363A mutants of PPARc. Data are
expressed relative to the levels of vehicle-treated cells; these levels were set to 1. Results are expressed as means 6 1 S.D. of three independent
cultures. *P , 0.05 indicates values significantly different between 2 groups analyzed by using 2-way ANOVA.
www.nature.com/scientificreports
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Discussion
Recent pharmacological studies classify agonists of nuclear receptors
as full or partial agonists, depending on their transcriptional activ-
ities. The difference between these two types of agonist can be
explained in terms of the structural features of PPARc-LBD/agonist
complexes and whether they use the H12-mediated or non-H12-
mediated mechanism. The full agonists directly stabilize H12, allow-
ing it to dock against H3 and H1116,21. The coactivator-binding
interface is configured by this conformational change. In contrast,
the partial agonists have no direct contact with H12, predominantly
interacting with residues on H3 and B322. This classification also
provides a means to distinguish between the differences in activity
between the tin compounds (Figure 4). TPT, a full agonist as shown
by cell-based assays (Figure 4), has hydrophobic interactions with
Leu469 and Tyr473, stabilizing H12. In contrast, the hydrophobic
interactions of TBT with the side chains of Val339 and Ile341, located
in B3, displace TBT from H12. This structural feature of the TBT
complex suggests some limited agonistic activity for TBT, as
observed in the cell-based assay (Figure 4).
In both complexes, the protein backbones have almost the same
conformation, and the ligand volumes (TBT, 233 Å3; TPT, 245 Å3)
are very similar15. Thus, it is likely that both organotin compounds
Figure 5 | Mass spectrometry of the PPARc-LBD complex with TPT (A–C) or TBT (D, E) under non-denaturing conditions. Mass spectra show that
PPARc forms a complex with TPT (C) or TBT (E) in a 151 molar ratio. Mass patterns after the addition of aliquots of formic acid (A, D 5 3%,
B 5 1%) to the complex indicate that the dissociation of the interaction is caused by the unfolding of PPARc-LBD.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8520 | DOI: 10.1038/srep08520 5
would interact with PPARc-LBD in the same manner and show
similar transactivation activity. However, we found that they occupy
different spatial positions within the ligand-binding pocket that
result in different levels of activation. Of note, organotin compounds
are anchored to the Cys285 of PPARc by an ionic bond, which does
not impose strict angular or length constraints, unlike covalent
bonds. Moreover, PPARc-LBD has a relatively large binding pocket,
which can accommodate a diverse array of ligands16. Thus, TPT and
TBT can optimally adapt their positions depending on their specific
interactions with surrounding residues in the ligand-binding pocket,
even though their ligand volumes are almost the same. The origins of
positional preference are explained based on high-resolution struc-
tural analyses of the ligand-binding pocket, in which the side chains
of Phe and Tyr form a cluster on the side of H12. The phenyl rings of
TPT make it possible to form a network of p-p interactions, as shown
in Figure 6, which stabilizes the active conformation of H12 and
results in full agonistic activity. It is well known that p-p interactions
can have a significant influence on protein–ligand interactions23. In a
previous report10, we showed that TPT is powerful agonist for
PPARc but not for the other PPAR subtypes, a and d, which have
an isoleucine at the position corresponding to Phe363. The mech-
anism of subtype selectivity responsible for the presence of the p-p
interaction at Phe363 has been proposed for benzenesulfonamide
derivatives, which are selective PPARc agonists24. In fact, although
the transactivation of the F363A mutant of PPARc by TPT was
significant lower than that of wild-type, no difference in activity
was observed for TBT (Figure 4). These results indicate that the
p-p interactions contribute to the high transcriptional activity of
TPT for PPARc.
In contrast to TPT, TBT had no direct contact with H12 as shown
in Figure 3A. This observation is consistent with previous findings
where TBT behaved as a weak agonist against PPARc and acted
mainly on RXRa15. Although no direct interaction between the orga-
notin and H12 was observed in the case of the RXRa/TBT complex, a
specific interaction between the tin atom and Cys432 in H11 of
RXRa might stabilize the helix 12. However, Cys285 of PPARc,
which is located at H3, offers an anchoring point to the organotin
but is not sufficient to position the ligand such that it can support the
active conformation of H12 (see Supplementary Fig. S6 online).
In conclusion, here we show the structural basis for the strong
activation of PPARc by TPT. We previously showed that hCG
secretion in human choriocarcinoma cells, which is upregulated by
RXR-PPARc signaling pathways, is powerfully induced by phenyltin
compounds, relative to butyltin compounds9,12,13 and concluded that
the differences in toxicological response caused by these organotins
depended on their potencies as agonists for PPARc and RXR9. Our
current observations show that the mode of action of organotin
compounds, via RXR-PPARc signaling pathways, is strongly influ-
enced by their chemical structures.
Methods
Cell culture. Cells of the human choriocarcinoma cell line JEG-3 (ATCC No. HTB-
36) were obtained from ATCC (Manassas, VA). JEG-3 cells were cultured in MEM
with 2 mM L-glutamine, 0.1 mM MEM nonessential amino acid solution
(Invitrogen, Carlsbad, CA), and 10% fetal calf serum (FCS). The cells were
maintained at 37uC in a humidified atmosphere containing 5% CO2.
Plasmid construction. Full-length cDNA of human PPARc was amplified by RT-
PCR using mRNA from JEG-3 cells. For the PPARc transactivation assay, the
amplified hPPARc fragment was cloned into the pM vector (Clontech, Mountain
View, CA). The resulting GAL4 DNA-binding domain- (DBD) fused hPPARc
expression vector was termed pM-hPPARc. pM-hPPARc mutant constructs,
carrying a Cys285 or Phe363 to Ala mutation, were generated by site-directed
mutagenesis of the pM-hPPARc plasmid using the PrimeSTAR mutagenesis basal kit
(Takara Bio, Shiga, Japan). The sequences of the mutagenic primers are shown in
Supplementary Table S1, online.
PPARc transactivation assay. The responsiveness of PPARc to organotin
compounds was measured by using a chimeric receptor consisting of the GAL4-DBD
and PPARc, pM-hPPARc, with a luciferase (LUC) reporter system, p43UAS-tk-luc,
which is a LUC reporter construct containing four copies of the GAL4 binding site
[upstream activating sequence (UAS) of GAL4] followed by the thymidine kinase
promoter9,10. Transient transfection assays were performed in JEG-3 cells with
Lipofectamine reagent (Invitrogen). The cells (3 3 104) were seeded in 24-well plates
24 h before transfection with pM-hPPARc and p43UAS-tk-luc. At 24 h after
transfection, compounds in 0.1% DMSO were added to the cells, which were then
cultured in medium supplemented with 1% charcoal-stripped FCS. The cells were
harvested 24 h later, and extracts were assayed for firefly LUC activity. To normalize
firefly LUC activity, the Renilla LUC control reporter construct pGL 4.74-TK
(Promega, Madison, WI) was co-transfected as an internal standard. The results are
expressed as the average of measurements of at least quadruplicate samples. Data
from the cell-based transcriptional activation assay were analyzed by using two-way
ANOVA, with multiple comparisons obtained with the Tukey-HSD test. A P value of
,0.05 was used to indicate statistical significance. All statistical analyses were
performed with SPSS software (Chicago, IL).
Protein expression and purification. The human PPARc-LBD (residues 202–477) was
cloned into the pGEX-6P-3 vector. E. coli Rosetta (DE3) cells (Novagen) transformed by
the plasmid were grown at 37uC in LB medium containing 20 mg/ml chloramphenicol
and 50 mg/ml ampicillin to A600 5 0.6, and were induced by the addition of IPTG to a
final concentration of 0.1 mM. Then, the cells were grown for 12–14 h at 10uC.
Harvested cells were lysed by sonication. After the supernatant was applied to a GSTrap
HP column (GE Healthcare), 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA,
and 1 mM DTT with 100 U PreScission protease (GE Healthcare) was applied to same
column, to remove the GST tag. PPARc-LBD was eluted with the same buffer and
dialyzed against 20 mM Tris-HCl (pH 8.0). Then PPARc-LBD was applied to a HiTrap
Q HP column (GE Healthcare) and eluted with an NaCl gradient (0.01–0.5 M). The
fractions containing PPARc-LBD were pooled and dialyzed against 20 mM Tris-HCl
(pH 7.5), 100 mM NaCl, 5 mM EDTA, and 2 mM DTT. PPARc-LBD was
concentrated to 5 mg/mL by using Amicon Ultra 15 concentrator (Millipore).
Crystallization, data collection, and structure determination. We performed co-
crystallization with organotin compounds and PPARc-LBD by using the sitting-drop
vapor-diffusion method at 277 K. Because the organotin compounds have poor
aqueous solubility, an excess of each compound was added as powder to the protein
solution and incubated for several hours to obtain the PPARc-LBD/organotin complex.
Insoluble compound was removed before crystallization by centrifugation followed by
filtration through a 0.2-mm membrane filter. Crystals were obtained from drops derived
from 1 mL of protein solution (20 mM Tris–HCl, pH 7.5, 100 mM NaCl, 2 mM
EDTA, 5 mM DTT) mixed with an equal volume of crystallization buffer (100 mM
Tris-HCl, pH 8.5 160 mM CH3COONH4, 19%–23% PEG4000). Diffraction data were
collected at 100 K on beamline 6A or 17A of Photon Factory, KEK (Tsukuba, Japan),
and beamline BL38B1 of SPring-8 (Hyogo, Japan), and were indexed, integrated, and
scaled by using HKL2000. All structures were solved by use of the molecular
replacement method using MOLREP from the CCP4 suite with the previously reported
PPARc-LBD structure (PDB 1PRG) as an initial search model. Structural refinement
and the addition of water molecules were performed by using Coot and REFMAC5.
The final structures were checked and validated by MolProbity. The atomic coordinates
were deposited in the Protein Data Bank (PDB) as entry code 3WJ4 and 3WJ5 for
PPARc-LBD/TBT and PPARc-LBD/TPT, respectively. The statistics for the diffraction
data collection and structural refinement are shown in Table 1.
Mass spectrometry. The concentration of PPARc-LBD was fixed at 1 mM, and an
excess amount of TPT or TBT was added. After dilution with buffer (20 mM Tris and
Figure 6 | The p-p interactions in the PPARc-LBD/TPT complex. The
distances between the nearest neighbor carbon atoms of the aromatic rings
are indicated.
www.nature.com/scientificreports
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150 mM NaCl pH 7.5) to 10 mM, sample solutions of PPARc-LBD, PPARc-LBD/
TPT, and PPARc-LBD/TBT were subjected to a buffer exchange with 150 mM
ammonium acetate, pH 7.5, by passing them through mini gel filtration columns
(BioRad) prior to analysis. All samples were analyzed by use of nanoflow electrospray
using in-house capillaries prepared as described previously25. Samples were loaded
into capillaries, and spectra were recorded on a modified Synapt HDMS mass
spectrometer (Waters), which provides the molecular mass of a protein complex
formed through a non-covalent interaction26. All mass spectra were calibrated against
cesium iodide and analyzed by Mass Lynx software (Waters). Typical conditions
included 2–3 mL of aqueous protein solution, capillary voltage of 1.1–1.7 kV, cone
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